Personalized medicine in oncology: Where have we come from and where are we going?

Pharmacogenomics

Volumn 14, Issue 8, 2013, Pages 931-939

  André, Fabrice ^a   Ciccolini, Joseph ^b   Spano, Jean Philippe ^c   Penault Llorca, Frédérique ^d   Mounier, Nicolas ^e   Freyer, Gilles ^f   Blay, Jean Yves ^g   Milano, Gérard ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d CENTRE JEAN PERRIN   (France)

^e UNIVERSITY HOSPITAL OF NICE   (France)

^f HOSPICES CIVILS DE LYON   (France)

^g CENTRE LÉON BÉRARD   (France)

^h CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

biomarkers; genomics; personalized medicine; pharmacogenetics; pharmacokinetics

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PAZOPANIB; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SORAFENIB; SUNITINIB; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; DRUG MONITORING; DRUG RESEARCH; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOMICS; HUMAN; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; ONCOLOGY; PANCREAS CANCER; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR GENOMICS; UNSPECIFIED SIDE EFFECT;

HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PHARMACOGENETICS; PROSPECTIVE STUDIES; SYSTEMS BIOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 84878821957     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.79     Document Type: Review

References (65)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Schmidt C. From genome to drugs: where do we stand J. Natl Cancer Inst. 103, 996-997 (2011).
3. Vesell ES. Pharmacogenetics. N. Engl. J. Med. 287(18), 904-909 (1972).
4. Ciccolini J, Gross E, Dahan L et al. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope Clin. Colorectal Cancer 9, 224-228 (2010).
5. Fety R, Rolland F, Barberi-Heyob M et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin. Cancer Res. 4, 2039-2045 (1998). (Pubitemid 28415645)
6. Walko CM, McLeod HL. Will we ever be ready for blood level-guided therapy J. Clin. Oncol. 26(13), 2078-2079 (2008).
7. Dupuis C, Mercier C, Yang C et al. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs 19(3), 267-273 (2008).
8. Mercier C, Ciccolini J, Pourroy B et al. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. Ther. Drug Monit. 28(2), 212-218 (2006). (Pubitemid 44314951)
9. Picard S, Titier K, Etienne G et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109, 3496-3499 (2007). (Pubitemid 46572540)
10. Teng JF, Mabasa VH, Ensom MH. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther. Drug Monit. 34, 85-97 (2012).
11. Di Gion P, Kanefendt F, Lindauer A et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin. Pharmacokinet. 50(9), 551-603 (2011).
12. Azzopardi N, Lecomte T, Ternant D et al. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin. Cancer Res. 17(19), 6329-6337 (2011).
13. Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin. Biol. Ther. 5(Suppl. 1), S37-S47 (2005). (Pubitemid 41243344)
14. Avastin(r), package insert, Genentech Inc., CA, USA (2006).
15. Lee SY, McLeod HL. Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. J. Pathol. 223, 15-27 (2011).
16. Mercier C, Ciccolini J. Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit Trends Pharmacol. Sci. 28, 597-598 (2007). (Pubitemid 350176603)
17. Gamelin E, Delva R, Jacob J et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 2099-2105 (2008).
18. Mercier C, Brunet C, Yang CG et al. Pharmacoeconomic study in head and neck cancer patients: impact of prospective DPD deficiency screening with 5-Fluorouracil (5-FU) dose tailoring on toxicities-related costs. J. Clin. Oncol. 27, 15S (2009) (Suppl. abstract 6515).
19. Toffoli G, Cecchin E, Gasparini G et al. Genotype-driven Phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 866-871 (2010).
20. Freyer G, Duret A, Milano G et al. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. Anticancer Res. 31, 359-366 (2011).
21. Tan BR, Thomas F, Myerson RJ et al. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J. Clin. Oncol. 29, 875-883 (2011).
22. Regan MM, Leyland-Jones B, Bouzyk M et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J. Natl Cancer Inst. 104, 441-451 (2012).
23. Rae JM, Drury S, Hayes DF et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J. Natl Cancer Inst. 104, 452-460 (2012).
24. Kelly CM, Pritchard KI. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J. Natl Cancer Inst. 104, 427-428 (2012).
25. Sledge GW Jr. The challenge and promise of the genomic era. J. Clin. Oncol. 30, 203-209 (2012).
26. Ferté C, André F, Soria JC. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat. Rev. Clin. Oncol. 7, 367-380 (2010).
27. Blank PR, Moch H, Szucs TD et al. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin. Cancer Res. 17, 6338-6346 (2011).
28. Dollery CT. Beyond genomics. Clin. Pharmacol. Ther. 82, 366-370 (2007). (Pubitemid 47414367)
29. Bria E, Milella M, Cuppone F et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann. Oncol. 22, 2277-2285 (2011).
30. Erdem L, Giovannetti E, Leon LG, Honeywell R, Peters GJ. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr. Top Med. Chem. 12, 1649-1659 (2012).
31. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714 (2012).
32. Goodwin R, Giaccone G, Calvert H et al. Targeted agents: how to select the winners in preclinical and early clinical studies Eur. J. Cancer 48, 170-178 (2012).
33. Vogelzang NJ, Benowitz SI, Adams S et al. Clinical cancer advances 2011: annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol. 30, 88-109 (2012).
34. Ratain MJ, Glassman RH. Biomarkers in Phase I oncology trials: signal, noise, or expensive distraction Clin. Cancer Res. 13, 6545-6548 (2007). (Pubitemid 350206786)
35. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
36. Laurent-Puig P, Lièvre A, Blons H. Beyond the KRAS test. Eur. J. Cancer 45, 398-399 (2009).
37. Weng L, Zhang L, Peng Y, Huang RS. Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics 14, 315-324 (2013).
38. Joosse SA, Pantel K. Biologic challenges in the detection of circulating tumor cells. Cancer Res. 73, 8-11 (2013).
39. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin. Pharmacol. Ther. 93, 98-104 (2013).
40. Browning SR, Browning BL. Haplotype phasing: existing methods and new developments. Nat. Rev. Genet. 12, 703-714 (2011).
41. Baker M. Big biology: the 'omes puzzle. Nature 494(7438), 416-419 (2013).
42. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J. Natl Cancer Inst. 96, 990-997 (2004). (Pubitemid 39162641)
43. El-Maraghi RH, Eisenhauer EA. Review of Phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in Phase III. J. Clin. Oncol. 26, 1346-1354 (2008).
44. Meille C, Gentet JC, Barbolosi D et al. New adaptive method for Phase I trials in oncology. Clin. Pharmacol. Ther. 83, 873-881 (2008). (Pubitemid 351704918)
45. Yap TA, Sandhu SK, Workman P et al. Envisioning the future of early anticancer drug development. Nat. Rev. Cancer 10, 514-523 (2010).
46. Olmos D, Tan DS, Jones RL et al. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 16, 183-194 (2010).
47. Goodwin R, Giaccone G, Calvert H et al. Targeted agents: how to select the winners in preclinical and early clinical studies Eur. J. Cancer 48, 170-178 (2012).
48. Scher HI, Nasso SF, Rubin EH et al. Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clin. Cancer Res. 17, 6634-6640 (2011).
49. Gonzalez-Angulo AM, Hortobagyi GN. Is there an ideal way to combine trastuzumab with chemotherapy J. Clin. Oncol. 29, 4474-4476 (2011).
50. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 28, 4390-4399 (2010).
51. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 30(Suppl. 1), S9-S14 (2010).
52. Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J. Biomed. Biotechnol. 2011, 379123 (2011).
53. Paz-Ares LG, Gomez-Roca C, Delord JP et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 29, 3783-3790 (2011).
54. Bibeau F, Lopez-Crapez E, Di Fiore F et al. Impact of Fc{g}RIIa-Fc{g}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27, 1122-1129 (2009).
55. Dahan L, Norguet E, Etienne-Grimaldi MC et al. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer 11, 496 (2011).
56. Verweij J. Clinical trials in drug development: a minimalistic approach. Curr. Opin. Oncol. 24(3), 332-337 (2012).
57. Taube SE, Lively T. Challenges in drug and biomarker co-development. Recent Results Cancer Res. 195, 229-239 (2012).
58. de Souza JA, Olopade OI. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin. Oncol. 38, 263-273 (2011).
59. Ciccolini J, Mercier C, Dahan L et al. Integrating pharmacogenetics into gemcitabine dosing-time for a change Nat. Rev. Clin. Oncol. 8, 439-444 (2011).
60. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364, 1144-1153 (2011).
61. Von Hoff DD, Stephenson JJ Jr, Rosen P et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 28, 4877-4883 (2010).
62. Andre F, Nowak F, Arnedos M et al. Biomarker discovery, development, and implementation in France: a report from the French national cancer institute and cooperative groups. Clin. Cancer Res. 18, 1555-1560 (2012).
63. Garrido-Laguna I, Hidalgo M, Kurzrock R. The inverted pyramid of biomarker-driven trials. Nat. Rev. Clin. Oncol. 8, 562-566 (2011).
64. Gao B, Yeap S, Clements A et al. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J. Clin. Oncol. 30, 4017-4025 (2012).
65. Patel JN, Mandock K, McLeod HL. Clinically relevant cancer biomarkers and pharmacogenetic assays. J. Oncol. Pharm. Pract. doi:10.1177/1078155212473862 (2013) (Epub ahead of print).